PharmaFocus Today – media

Seizing the opportunity of the Chinese market, multinational pharmaceutical companies saw revenue growth last year

Recently, the “report cards” of multinational pharmaceutical companies in 2024 have been released one after another. Overall, the leading multinational pharmaceutical companies have shown major trends such as revenue growth, significant volume growth of innovative products, and accelerated development of precise mergers and acquisitions. As one of the important pharmaceutical markets in the world, the Chinese market remains the focus of competition among major pharmaceutical companies. “Drug King” Competition According to the performance announced by multinational pharmaceutical companies, Johnson & Johnson ranked first with a total revenue of US$88.821 billion, and Roche, Merck, and Pfizer ranked second, third, and fourth with revenues of more than US$60 billion, respectively. AbbVie, AstraZeneca, and Novartis followed closely behind, with revenues exceeding US$50 billion. Bristol-Myers Squibb (BMS), Eli Lilly, Sanofi, Novo Nordisk, and GlaxoSmithKline all had revenues of more than US$40 billion. In the competition among multinational pharmaceutical companies, annual sales of tens of ...
- Source: drugdu
- 34
- February 21, 2025
Can Chengda Bio turn the tide?

Recently, Chengda Bio issued an announcement that its actual controller is intended to be changed from the State-owned Assets Supervision and Administration Commission of the People’s Government of Liaoning Province (hereinafter referred to as “Liaoning Provincial SASAC”) to no actual controller. Behind this is that Shaoguan Gaoteng became the controlling shareholder of Liaoning Chengda through the board of directors election, and indirectly controlled 54.67% of Chengda Bio’s equity through Liaoning Chengda. Shaoguan Gaoteng is a wholly-owned subsidiary of Guangdong Private Investment Co., Ltd. (hereinafter referred to as “Guangdong Private Investment”), and there is no actual controller after the equity structure is penetrated. At the same time, Chengda Bio also issued a tender offer announcement. The tender offerer is Shaoguan Gaoteng, which will acquire the unrestricted tradable shares held by all other shareholders of Chengda Bio except Liaoning Chengda, and will not terminate Chengda Bio’s listing status. The tender offer price ...
- Source: drugdu
- 33
- February 21, 2025
A drop of blood can predict Alzheimer’s disease 15 years in advance. When can it be realized?

“With the advancement of technology, we can achieve an accuracy rate of more than 90% in peripheral blood diagnosis of Alzheimer’s disease. Now many diagnostic companies have contacted us to carry out results transformation.” Recently, Alzheimer’s disease (hereinafter referred to as AD) expert Yu Jintai revealed to Jiemian News. Yu Jintai is the deputy dean of Fudan University Institute of Science and Technology, director of the Research Department of Shanghai Medical College of Fudan University, and deputy director of the Department of Neurology of Huashan Hospital Affiliated to Fudan University. Previously, he and the team of Professor Mao Ying, dean of Huashan Hospital, jointly with the team of Professor Feng Jianfeng and Cheng Wei of Fudan Brain-like Intelligence Science and Technology Research Institute, led a study to find a new AD peripheral blood protein target. Blood draws can predict the risk of dementia 15 years in advance, with an accuracy ...
- Source: drugdu
- 35
- February 21, 2025
collision of targets and technologies

In 1982, Weinberg and other laboratories discovered HRAS in human bladder cancer cells T24/EJ, making RAS the first human tumor gene discovered. Subsequently, other tumor genes KRAS and NRAS were also discovered. However, in the following decades, no targeted drugs for the KRAS gene have been successfully developed, and KRAS is considered an “undruggable” target. In 2021, the first KRAS G12C inhibitor, Sotorasib, was launched, making KRAS a hot target in the field of oncology. However, its clinical and commercialization progress after its launch was not satisfactory. Therefore, pan-KRAS inhibitors that can target multiple mutation forms of the KRAS gene have become a new research direction in the field of KRAS targeted drugs. The close connection between KRAS gene and cancer The full name of the KRAS gene is Kirsten Rat Sarcoma Viral Oncogene Homolog, which means “Kirsten rat sarcoma viral oncogene homolog” in Chinese. It is a proto-oncogene that ...
- Source: drugdu
- 35
- February 21, 2025
When can a drop of blood predict Alzheimer’s disease 15 years in advance| Shanghai Acceleration Run

With the advancement of technology, we can improve the accuracy of peripheral blood diagnosis of Alzheimer’s disease to over 90%. Now, multiple diagnostic companies have contacted us to carry out achievement transformation. Recently, Alzheimer’s disease (AD) expert Yu Jintai revealed to Interface News. Yu Jintai is the Vice Dean of the Institute of Science and Technology at Fudan University, the Director of the Research Department at Fudan University Shanghai Medical College, and the Deputy Director of the Neurology Department at Fudan University Affiliated Huashan Hospital. Previously, he and the team led by Professor Mao Ying, the director of Huashan Hospital, collaborated with Professor Feng Jianfeng and Professor Cheng Wei from Fudan Institute of Brain Intelligence Science and Technology to conduct a study that identified new peripheral blood protein targets for Alzheimer’s disease. By drawing blood, the risk of dementia can be predicted 15 years in advance, with an accuracy ...
- Source: drugdu
- 41
- February 20, 2025
Real life submission to the Hong Kong Stock Exchange with CICC as the exclusive sponsor

Real life submission to the main board of the Hong Kong Stock Exchange, with China International Capital Corporation as its exclusive sponsor. The prospectus shows that RealBio is a biotechnology company driven by innovative research and development, focusing on the development, manufacturing, and commercialization of innovative drugs for the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases. Our mission is to improve human health through true innovation, especially in the fields of antiviral and anti-tumor treatments, exploring and addressing the issue of drug resistance in existing treatment options. The company aims to seek updated and better treatment options to address unmet clinical needs. With rich experience in drug development, RealBio has established a comprehensive research and development platform, including a highly selective new nucleoside broad-spectrum anti-tumor drug development platform, TOPO1 inhibitor and XDC drug development platform, drug target discovery and validation platform, and innovative drug design and optimization ...
- Source: drugdu
- 41
- February 20, 2025
Top 10 Most Valuable Innovative Devices in DeepSeek’s Eyes

At the beginning of the Spring Festival, DeepSeek quickly became popular, and then the topic of AI software predicting the future became a hot topic, sparking discussions among netizens. Similar topics such as “using DeepSeek to predict the future development direction of the pharmaceutical industry”, “predicting the top ten golden tracks for medical devices in 2025”, and “predicting the investment trend in the medical device industry in 2025” are constantly emerging. Is AI prediction reliable? To explore this question and continue the AI speculation, in DeepSeek’s eyes, who will be the top 10 most valuable innovative medical devices in China? Today we will pose this question to DeepSeek, using its intelligent analysis to examine the current development status of innovative medical devices in China. DeepSeek defines innovative medical devices Value evaluation criteria for innovative medical devices – According to the Special Approval Procedure for Innovative Medical Devices, selected products must ...
- Source: drugdu
- 36
- February 20, 2025
The first domestically produced modified new drug of docetaxel has successfully gone global

Today (February 18th), Zhuhai Beihai Biotechnology Co., Ltd. (referred to as “Beihai Biotechnology”) announced that it has reached a significant strategic cooperation with Zydus Lifesciences, granting its new drug BEIBRAY (docetaxel BH009) exclusive commercialization rights in the US market. The news pointed out that BEIZRA is the first improved new drug in China to successfully achieve authorization for export to the United States in recent years. According to the terms of the agreement, Beihai Biotechnology will be responsible for the production and supply of BEIBRAY, while Zydus Pharmaceuticals, a US subsidiary of Zydus, will be responsible for the commercialization of the product in the United States. Beihai Biotechnology will receive a down payment of $15 million (to be paid after the agreement is signed) and $10 million (to be paid after the first product delivery), as well as multiple sales milestone payments and high double-digit profit sharing. According to a ...
- Source: drugdu
- 38
- February 20, 2025
Received the approval notice for re-registration of Orlistat Capsules

On February 17, Watson Pharmaceuticals announced that the company recently received the “Drug Re-registration Approval Notice” for the company’s product Orlistat Capsules approved and issued by the Chongqing Municipal Drug Administration. The drug approval number of Orlistat Capsules is valid until January 22, 2030. The product was originally a cooperative product of the company. At the end of 2021, the company reached a further agreement with its partners to sell and operate Orlistat Capsules under its own brand “Quchang”. At present, this variety has little impact on the company’s operating income and profits. It will not have a significant impact on the company’s operating performance in the short term. https://finance.eastmoney.com/a/202502173321214653.html
- Source: drugdu
- 35
- February 20, 2025
Drugs received approval notice for Phase II/III clinical trials

Baili Tianheng (688506) announced on the evening of February 18 that the company recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Medical Products Administration (NMPA), and the Phase II/III clinical trial of the company’s independently developed innovative biological drug BL-M07D1 (HER2-ADC) for injection was approved. As of the disclosure date of this announcement, in addition to the newly approved clinical trial, BL-M07D1 is being evaluated as a single drug or in combination in 10 Phase I/II/III clinical trials in China and the United States. The various clinical studies include patients with various HER2-expressing/mutated solid tumors (including non-small cell lung cancer, breast cancer, urothelial carcinoma, gynecological tumors and digestive tract tumors). https://finance.eastmoney.com/a/202502183322435142.html
- Source: drugdu
- 34
- February 20, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.